339-40-2Relevant articles and documents
-
Mooradian,Leubner
, p. 2067 (1947)
-
Combining organometallic reagents, the sulfur dioxide surrogate DABSO, and amines: A One-pot preparation of sulfonamides, amenable to array synthesis
Deeming, Alex S.,Russell, Claire J.,Willis, Michael C.
supporting information, p. 1168 - 1171 (2015/01/30)
We describe a method for the synthesis of sulfonamides through the combination of an organometallic reagent, a sulfur dioxide equivalent, and an aqueous solution of an amine under oxidative conditions (bleach). This simple reaction protocol avoids the need to employ sulfonyl chloride substrates, thus removing the limitation imposed by the commercial availability of these reagents. The resultant method allows access to new chemical space, and is also tolerant of the polar functional groups needed to impart favorable physiochemical properties required for medicinal chemistry and agrochemistry. The developed chemistry is employed in the synthesis of a targeted 70 compound array, prepared using automated methods. The array achieved a 93% success rate for compounds prepared. Calculated molecular weights, lipophilicities, and polar surface areas are presented, demonstrating the utility of the method for delivering sulfonamides with drug-like properties.
Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains
Zhang, Guangtao,Plotnikov, Alexander N.,Rusinova, Elena,Shen, Tong,Morohashi, Keita,Joshua, Jennifer,Zeng, Lei,Mujtaba, Shiraz,Ohlmeyer, Michael,Zhou, Ming-Ming
, p. 9251 - 9264 (2014/01/06)
BRD4, characterized by two acetyl-lysine binding bromodomains and an extra-terminal (ET) domain, is a key chromatin organizer that directs gene activation in chromatin through transcription factor recruitment, enhancer assembly, and pause release of the RNA polymerase II complex for transcription elongation. BRD4 has been recently validated as a new epigenetic drug target for cancer and inflammation. Our current knowledge of the functional differences of the two bromodomains of BRD4, however, is limited and is hindered by the lack of selective inhibitors. Here, we report our structure-guided development of diazobenzene-based small-molecule inhibitors for the BRD4 bromodomains that have over 90% sequence identity at the acetyl-lysine binding site. Our lead compound, MS436, through a set of water-mediated interactions, exhibits low nanomolar affinity (estimated Ki of 30-50 nM), with preference for the first bromodomain over the second. We demonstrated that MS436 effectively inhibits BRD4 activity in NF-κB-directed production of nitric oxide and proinflammatory cytokine interleukin-6 in murine macrophages. MS436 represents a new class of bromodomain inhibitors and will facilitate further investigation of the biological functions of the two bromodomains of BRD4 in gene expression.
